中文产业新闻评分49Chinese source
恒瑞医药将口服双靶GLP-1药物以最高26亿美元授权给诺和诺德
速递｜恒瑞每周口服双靶GLP-1卖诺和，26亿美元背后的减肥药口服抢位战
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
速递｜恒瑞每周口服双靶GLP-1卖诺和，26亿美元背后的减肥药口服抢位战
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.